CRISPR Therapeutics AG

CRSP Nasdaq CIK: 0001674416

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation Switzerland
Country Switzerland
Business Address BAARERSTRASSE 14, ZUG, ,
Mailing Address BAARERSTRASSE 14, ZUG, ,
Phone 6173154600
Fiscal Year End 1231
EIN 473173478

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report March 24, 2026 View on SEC
4 Insider stock transaction report March 24, 2026 View on SEC
4 Insider stock transaction report March 24, 2026 View on SEC
4 Insider stock transaction report March 24, 2026 View on SEC
4 Insider stock transaction report March 17, 2026 View on SEC
4 Insider stock transaction report March 17, 2026 View on SEC
4 Insider stock transaction report March 17, 2026 View on SEC
4 Insider stock transaction report March 17, 2026 View on SEC
8-K Current report of material events March 16, 2026 View on SEC
4 Insider stock transaction report March 12, 2026 View on SEC

Annual Reports

10-K February 12, 2026
  • Successful launch of CASGEVY (exagamglogene autotemcel) for sickle cell disease and transfusion-dependent beta thalassemia, securing landmark regulatory approvals in the U.S., Europe, and UK.
  • Reported total revenue of $350 million for fiscal year 2025, a substantial increase from $120 million in 2024, driven by collaboration revenue and initial CASGEVY sales.
View Analysis

Insider Trading

STRONG SELL 4 insiders 22 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.